Apogee Therapeutics Statistics
Total Valuation
APGE has a market cap or net worth of $2.71 billion. The enterprise value is $1.97 billion.
Important Dates
The last earnings date was Tuesday, November 12, 2024, before market open.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
APGE has 56.90 million shares outstanding. The number of shares has increased by 272.26% in one year.
| Current Share Class | 43.42M |
| Shares Outstanding | 56.90M |
| Shares Change (YoY) | +272.26% |
| Shares Change (QoQ) | +0.50% |
| Owned by Insiders (%) | 2.09% |
| Owned by Institutions (%) | 80.81% |
| Float | 27.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.70 |
| P/TBV Ratio | 3.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.39, with a Debt / Equity ratio of 0.02.
| Current Ratio | 16.39 |
| Quick Ratio | 16.28 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -25.65% and return on invested capital (ROIC) is -19.27%.
| Return on Equity (ROE) | -25.65% |
| Return on Assets (ROA) | -18.51% |
| Return on Capital (ROIC) | -19.27% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.61M |
| Employee Count | 91 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +105.47% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +105.47% |
| 50-Day Moving Average | 50.84 |
| 200-Day Moving Average | 50.58 |
| Relative Strength Index (RSI) | 49.24 |
| Average Volume (20 Days) | 623,086 |
Short Selling Information
The latest short interest is 7.36 million, so 12.94% of the outstanding shares have been sold short.
| Short Interest | 7.36M |
| Short Previous Month | 6.62M |
| Short % of Shares Out | 12.94% |
| Short % of Float | 26.78% |
| Short Ratio (days to cover) | 16.72 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -178.14M |
| Pretax Income | -103.55M |
| Net Income | -146.66M |
| EBITDA | n/a |
| EBIT | -178.14M |
| Earnings Per Share (EPS) | -$2.77 |
Full Income StatementBalance Sheet
The company has $526.05 million in cash and $12.14 million in debt, giving a net cash position of $741.66 million or $13.03 per share.
| Cash & Cash Equivalents | 526.05M |
| Total Debt | 12.14M |
| Net Cash | 741.66M |
| Net Cash Per Share | $13.03 |
| Equity (Book Value) | 734.40M |
| Book Value Per Share | 12.91 |
| Working Capital | 501.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$133.21 million and capital expenditures -$1.32 million, giving a free cash flow of -$134.53 million.
| Operating Cash Flow | -133.21M |
| Capital Expenditures | -1.32M |
| Free Cash Flow | -134.53M |
| FCF Per Share | -$2.36 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |